Integral DiagnosticsITGDF 72 5-Year Yield-on-Cost % is 0.93 as of Jul. 12, 2026, which is 26% below its 10-year median of 1.26. GuruFocus rates ITGDF with a GF Score™ of 72/100 and a GF Value™ of $3.54 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 65 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 63.08% on this metric.
Integral Diagnostics's yield on cost for the quarter that ended in Dec. 2025 was 0.93.
The historical rank and industry rank for Integral Diagnostics's 5-Year Yield-on-Cost % or its related term are showing as below:
ITGDF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.83 Med: 1.26 Max: 2.34
Current: 0.93
During the past 10 years, Integral Diagnostics's highest Yield on Cost was 2.34. The lowest was 0.83. And the median was 1.26.
ITGDF's 5-Year Yield-on-Cost % is ranked worse than 63.08% of 65
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.45
vs ITGDF: 0.93
Integral Diagnostics (OTCPK:ITGDF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Integral Diagnostics 5-Year Yield-on-Cost % Related Terms
ITGDF vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's 5-Year Yield-on-Cost % falls into.
Integral Diagnostics 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Integral Diagnostics (ITGDF) has a 5-Year Yield-on-Cost % of 0.93 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Integral Diagnostics and its competitors. This is 26% below median its historical median of 1.26. Over the past decade, Integral Diagnostics' 5-Year Yield-on-Cost % has ranged from 0.83 to 2.34. According to the industry distribution chart, Integral Diagnostics ranks #41 out of 65 companies in the Medical Diagnostics & Research industry, placing it in the top 63.1%.
Is Integral Diagnostics' 5-Year Yield-on-Cost % too high?
Integral Diagnostics' current 5-Year Yield-on-Cost % of 0.93 is 26% below median its 10-year median of 1.26. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 2.34. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.45. Integral Diagnostics' value of 0.93 is 62% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #41 out of 65 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #41 out of 65 companies for 5-Year Yield-on-Cost %. This places Integral Diagnostics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. Integral Diagnostics' value of 0.93 is 62% below this benchmark. Historically, Integral Diagnostics' own 5-Year Yield-on-Cost % has ranged from 0.83 to 2.34 over the past decade. While the company's 10-year median is 1.26 vs. the industry median of 2.45, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.45, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current 5-Year Yield-on-Cost % of 0.93 is 62% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current 5-Year Yield-on-Cost % is 0.93, which is 26% below median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ITGDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.54, compared to a current price of $2.61 — trading 26.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.93, which is 26% below median its 10-year median of 1.26 and 62% below the Medical Diagnostics & Research industry median of 2.45. Integral Diagnostics' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current 5-Year Yield-on-Cost % is 0.93 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ITGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of $2.61 is trading 26.2% below its estimated GF Value™ of $3.54.
GuruFocus considers Integral Diagnostics to be Significantly Overvalued.
Key valuation signals for ITGDF:
5-Year Yield-on-Cost %: 0.93 (26% below median its 10-year median of 1.26)
GF Value™: $3.54 vs. price of $2.61 (26.2% below fair value)
Industry Position: 62% below the Medical Diagnostics & Research median (#41 of 65)
No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
72GF Score
Get the complete analysis for ITGDF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITGDF has been successfully added to your 